0.167
Oragenics Inc stock is traded at $0.167, with a volume of 270.65M.
It is up +39.17% in the last 24 hours and down -14.32% over the past month.
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
See More
Previous Close:
$0.12
Open:
$0.27
24h Volume:
270.65M
Relative Volume:
59.99
Market Cap:
$3.59M
Revenue:
-
Net Income/Loss:
$-20.26M
P/E Ratio:
-0.0196
EPS:
-8.54
Net Cash Flow:
$-8.25M
1W Performance:
-12.11%
1M Performance:
-14.32%
6M Performance:
-47.81%
1Y Performance:
-91.73%
Oragenics Inc Stock (OGEN) Company Profile
Name
Oragenics Inc
Sector
Industry
Phone
813-286-7900
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
OGEN
Oragenics Inc
|
0.167 | 4.12M | 0 | -20.26M | -8.25M | -8.54 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Oragenics Inc Stock (OGEN) Latest News
OGEN stock touches 52-week low at $0.12 amid sharp annual decline By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.12 amid sharp annual decline - Investing.com Australia
Oragenics announces reverse stock split to begin June 3 By Investing.com - Investing.com South Africa
Oragenics (OGEN) Announces One-for-Thirty Reverse Stock Split | - GuruFocus
Oragenics announces reverse stock split to begin June 3 - Investing.com Australia
Oragenics Announces Reverse Stock Split to Boost Share Price - TipRanks
Oragenics (OGEN) Announces One-for-Thirty Reverse Stock Split | OGEN Stock News - GuruFocus
Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split - GlobeNewswire
Oragenics Hosts Neurotrauma Medicine Webinar Presentation - TipRanks
Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com - Defense World
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia - GlobeNewswire
Oragenics (OGEN) Gains Approval for Phase II Trial of Neuroprote - GuruFocus
Oragenics gains Australia’s nod for concussion therapy trial - Investing.com Australia
Oragenics gains Australia’s nod for concussion therapy trial By Investing.com - Investing.com Nigeria
Oragenics, Inc. Announces Approval to Initiate Phase II Concussi - GuruFocus
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia | OGEN Stock News - GuruFocus
Oragenics, Inc. to Host Management Update Webinar on May - GlobeNewswire
Oragenics, Inc. to Host Management Update Webinar on May 20, 202 - GuruFocus
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision | OGEN Stock News - GuruFocus
Oragenics, Inc. to Host Webinar on ONP-002 and Addressing Unmet Needs in Concussion Treatment - Nasdaq
CSW Industrials Announces Date for Fiscal Fourth Quarter and Full Year 2025 Earnings Release Conference Call - The Manila Times
Oragenics: Q1 Earnings Snapshot - New Haven Register
Oragenics (NYSE:OGEN) Now Covered by StockNews.com - Defense World
Oragenics Appoints New CEO and Amends Employment Terms By Investing.com - Investing.com Nigeria
Oragenics Appoints New CEO and Amends Employment Terms - Investing.com Australia
Oragenics Appoints Janet Huffman as CEO and CFO - TipRanks
StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN) - Defense World
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brai - GuruFocus
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference | OGEN Stock News - GuruFocus
Oragenics, Inc. to Present at the 15th Annual Traumatic Brain Injury Conference on Advances in mTBI Detection and Management - Nasdaq
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference - GlobeNewswire
Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com - Defense World
Oragenics, Inc. Announces Health and Disability Ethics Committee - GuruFocus
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial - The Manila Times
Oragenics Announces Health And Disability Ethics Committee Submission - MarketScreener
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - GlobeNewswire
Oragenics Inc Stock (OGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):